Impel Pharmaceuticals Inc.
IMPL · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -23.7% | 50.6% | -12.7% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 55.6% | 51.1% | 47.7% | 55.7% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -335.3% | -244.6% | -558.9% | -114% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -275% | -111.7% | -883.6% | -725.1% |
| EPS Diluted | -0.58 | -0.31 | -1.63 | -1.53 |
| % Growth | -87.1% | 81% | -6.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |